Liu, C., Lin, B., Wu, M., Song, Y., Ke, T., Chou, Y., Liu, C., Lin, C., Radojcic, V., Drake, C., & Yen, H. (2022). Adoptive transfer of IL‐4 reprogrammed Tc17 cells elicits anti‐tumour immunity through functional plasticity. Immunology, 166(3), 310–326. Portico. https://doi.org/10.1111/imm.13473

Gaydosik, A. M., Stonesifer, C. J., Khaleel, A. E., Geskin, L. J., & Fuschiotti, P. (2022). Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas. Clinical Cancer Research, 28(12), 2610–2622. https://doi.org/10.1158/1078-0432.ccr-21-4437

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. (2022). P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY. HemaSphere, 6, 420–421. https://doi.org/10.1097/01.hs9.0000844972.31512.dd

Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., … Curran, K. J. (2022). Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 6(7), 1961–1968. https://doi.org/10.1182/bloodadvances.2021006418

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Albitar, M., Zhang, H., Goy, A., Xu-Monette, Z. Y., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Huh, J., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., … Young, K. H. (2022). Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 12(2). https://doi.org/10.1038/s41408-022-00617-5

Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., … Schultz, L. M. (2022). Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 6(2), 600–610. https://doi.org/10.1182/bloodadvances.2021005564

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Houot, R., Poeschel, V., Altmann, B., Angel, S., Thurner, L., Illmer, T., Andre, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, O., Le Gouill, S., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., Hoffmann, J., Ziepert, M., … Held, G. (2022). Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, 6(2), e672. https://doi.org/10.1097/hs9.0000000000000672

Hill, B. T., Roth, C. J., Kositsky, R., Dave, T., Love, C., McKinney, M., Galal, A., Neff, J. L., Mian, A., Kendall, E., Ondrejka, S. L., Chiaramonte, M., Bhagat, G., Ofori, K., Reshef, R., Kovach, A. E., Sethi, T., Mason, E. F., Bhaskar, S., … Dave, S. S. (2021). Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 138(Supplement 1), 165–165. https://doi.org/10.1182/blood-2021-145764

Kadia, T. M., Pemmaraju, N., Yilmaz, M., Daver, N., Li, L., Lyu, M.-A., Huang, M., Zeng, K., Cook, R., Parmar, S., Mukherjee, S., Sadeghi, T., DiNardo, C. D., Issa, G. C., Jabbour, E. J., Borthakur, G., Jain, N., & Verstovsek, S. (2021). Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes. Blood, 138(Supplement 1), 3875–3875. https://doi.org/10.1182/blood-2021-153864

Scuoppo, C., Cai, B., Ofori, K., Scholze, H., Basso, K., Pasqualucci, L., & Dalla-Favera, R. (2021). Repurposing NAD Salvage Inhibitors for GCB Diffuse Large-B Cell Lymphoma. Blood, 138(Supplement 1), 789–789. https://doi.org/10.1182/blood-2021-151079

Pemmaraju, N., Cuglievan, B., Lasky, J. L., Kheradpour, A., Hijiya, N., Stein, A. S., & Pawlowska, A. B. (2021). Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. Blood, 138(Supplement 1), 2317–2317. https://doi.org/10.1182/blood-2021-150393

Chakraborty, R., Yan, Y., & Royal, M. (2021). A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 138(Supplement 1), 4763–4763. https://doi.org/10.1182/blood-2021-150783

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Sherman, M., Dong, J., Giovanetti, A., … Jacobson, C. (2021). Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 138(Supplement 1), 93–93. https://doi.org/10.1182/blood-2021-148473

Ricker, E. C., Estrella, B., Pazos, M. A., & Amengual, J. E. (2021). Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL. Blood, 138(Supplement 1), 2410–2410. https://doi.org/10.1182/blood-2021-153460

Park, J. H., Nikiforow, S., Kim, S., Hu, Z.-H., Moskop, A., Ahmed, S., Bilal Abid, M., Badar, T., Bredeson, C., Brown, V., Cairo, M. S., Díaz, M., Dholaria, B., Ganguly, S., Grover, N. S., Hanna, R., Hematti, P., Kohorst, M. A., Lazarus, H., … Perales, M.-A. (2021). Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 138(Supplement 1), 3880–3880. https://doi.org/10.1182/blood-2021-148652

Gillison, M., Awad, M., Twardowski, P., Sukari, A., Johnson, M., Lackner, R., Stein, M., DeCillis, A., Hernandez, R., Price, J., Mancini, K., Shainheit, M., Santone, G., Shukor, S., Bicak, E., Vemulapalli, V., Tjon, E., Flechtner, J., Davis, T., & Cohen, R. (2021). 485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. Regular and Young Investigator Award Abstracts, A515–A515. https://doi.org/10.1136/jitc-2021-sitc2021.485

Boda, A., Ager, C., Rajapakshe, K., Lea, S., Francesco, M. E. D., Jones, P., & Curran, M. (2021). 758 High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma. Regular and Young Investigator Award Abstracts, A793–A793. https://doi.org/10.1136/jitc-2021-sitc2021.758